We hosted an SCN2A Patient Community Webinar to explore our epilepsy programs PRAX222 and PRAX562 for SCN2A disorders.
Register Now: Praxis SCN2A Live Program Update Webinar on August 30, 2022, 6pm EDT
At Praxis Precision Medicines, we have a passion for developing new medicines for genetic epilepsy patients. We have two potential medicines for early onset SCN2A-Developmental Epileptic Encephalopathy (DEE) in clinical study planning phase.
International SCN2A Awareness Day is honored on 2/24 because the SCN2A gene is found on chromosome 2 at position 24.3.
At Praxis, we’re on a mission to develop novel therapies for SCN2A. We have compiled some questions we have received from you, along with our responses, to keep you informed on our journey. Additionally, we’re pleased to share some preliminary data around Ciitizen, an online platform that allows patients and caregivers an opportunity to advance research.
Praxis would like to thank all the families who participated in the International SCN2A Observational Study.
As we close out 2021, please accept our heartfelt thanks to you — the patients, parents, caregivers, and advocates who guide our work at Praxis. We are truly grateful to have you as partners as we travel together on the path of drug discovery and development. We recognize that behind every data point, is a person, an experience, and a voice — thank you for inspiring us with yours. Wishing you happiness and health in the new year.
At Praxis, we’re on a mission to develop novel therapies for SCN2A. We believe collaboration with the SCN2A community is critical in this work. We have compiled some questions we have received from you, along with our responses, to keep you informed on our journey.
We’re pleased to share this special Praxis Precision Medicines SCN2A and SCN8A community update. We invite you to learn more about what Praxis has been working on this Spring / Summer, and we thank you for your insights, interest, and participation.
Praxis has partnered with Ciitizen, an online platform that allows patients and caregivers an opportunity to advance research, to better understand variant characterization within SCN2A-gene mutations through the collection of EEG data from patients around the world. Earlier in 2021, Ciitizen and Praxis began partnering with Ciitizen on an observational study with SCN2A families in the United States and we are excited to expand this offering to families internationally.